2016, Número 5
Siguiente >>
Rev Invest Clin 2016; 68 (5)
Invasive and Complicated Pneumococcal Infection in Patients with Cancer
Zarco-Márquez S, Volkow-Fernández P, Velázquez-Acosta C, Echániz-Avilés G, Carnalla-Barajas MN, Soto-Noguerón A, Cornejo-Juárez P
Idioma: Ingles.
Referencias bibliográficas: 16
Paginas: 221-228
Archivo PDF: 112.58 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Shigayeva A, Rudnick W, Green K, et al; Toronto Invasive Bacterial Diseases Network. Invasive pneumococcal disease among immunocompromised persons: Implications for vaccination programs. Clin Infect Dis. 2016;62:139-47.
Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ; The SPAT Group. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect. 2010; 138:1804-10.
G arcía-Vidal C, Ardanuy C, Gudiol C, et al. Clinical and microbiology epidemiology of Streptococcus pneumoniae bacteremia in cancer patients. J Infect. 2012;65:521-7.
L in SH, Liao WH, Lai CC, et al. Comparison of clinical features, antimicrobial susceptibility, serotype distribution and outcomes of patients with hospital- and community-associated invasive pneumococcal disease. Int J Antimicrob Agents. 2010; 36:119-23.
Youssef S, Rodríguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients. Medicine. 2007;86:69-77.
Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing; 26th Informational Supplement, 2015. Approved Standard M100-S26. Wayne, PA, USA: Clinical and Laboratory Standards Institute.
Ikegame S, Wakamatsu K, Kumazoe H, et al. A retrospective analysis of 111 cases of pneumococcal pneumonia: clinical features and prognostic factors. Intern Med. 2012;51:37-43.
Christensen JS, Jensen TG , Kolmos HJ, Pedersen C, Lassen A. Bacteremia with Streptococcus pneumoniae: sepsis and other risk factors for 30-day mortality--A hospital-based cohort study. Eur J Clin Microbiol Infect Dis. 2012;31:2719-25.
Marrie TJ, Tyrrell GJ, Garg S, Vanderkooi OG. Factors predicting mortality in invasive pneumococcal disease in adults in Alberta. Medicine. 2011;90:171-9.
Bouza E, Pintado V, Rivera S, et al. Nosocomial bloodstream infections caused by Streptococcus pneumoniae. Clin Microbiol Infect. 2015;11:919-24.
E chániz-Avilés G, San Román-Álvarez L, Sánchez-Alemán M, Carnalla- Barajas MN, Soto-Noguerón A. Prevalence of Streptococcus pneumoniae serotype 19A before and after the introduction of the heptavalent conjugate vaccine in Mexico. Salud Publica Mex. 2014;56:266-71.
G eng Q, Zhang T, Ding Y, et al. Molecular characterization and antimicrobial susceptibility of Streptococcus pneumoniae isolated from children hospitalized with respiratory infections in Suzhou, China. PLoS One. 2014;9:e93752.
A rdanuy C, Marimón JM, Calatayud L, et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007- 2009): implications for future vaccination strategies. PLoS One. 2012;7:e43619.
Rubin LG , Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309-18.
SIREVA Network 2013. [Data for country and age groups about Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitides strains characteristics in invasive diseases]. Spanish. Washington, D.C., USA: World Health Organization; 2013. ISBN 978-92-75-31918-5. http://iris.paho.org/xmlui/ handle/123456789/31147.
T omic V, Dowzicky MJ. Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008). Ann Clin Microbiol Antimicrob. 2014;13:52.